Cargando…

Balancing the risks and benefits of biologic drugs in rheumatic disease: the case for romosozumab?

Detalles Bibliográficos
Autor principal:	Reid, David M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6974748/ https://www.ncbi.nlm.nih.gov/pubmed/32010237 http://dx.doi.org/10.1177/1759720X19895490

Ejemplares similares

Romosozumab for osteoporosis
Publicado: (2021)

Benefit-risk balance of COVID drugs. New prospects
por: Cracowski, Jean-Luc, et al.
Publicado: (2022)

Romosozumab for the treatment of osteoporosis
por: McClung, Michael R.
Publicado: (2018)

Romosozumab, clinical trials, and real-world care of patients with osteoporosis
por: Lewiecki, E. Michael
Publicado: (2020)

Romosozumab and cardiovascular safety in Japan
por: Takeuchi, Yasuhiro
Publicado: (2021)

Balancing risk and benefit during coronavirus
por: Sehn, Laurie H.
Publicado: (2020)

Romosozumab in osteoporosis: yesterday, today and tomorrow
por: Wu, Dong, et al.
Publicado: (2023)

Romosozumab for the treatment of osteoporosis in women: Efficacy, safety, and cardiovascular risk
por: Lim, Sian Yik
Publicado: (2022)

Romosozumab and antiresorptive treatment: the importance of treatment sequence
por: Cosman, Felicia, et al.
Publicado: (2022)

Trastuzumab cardiotoxiciy: the age-old balance of risk and benefit
por: Ewer, Michael S, et al.
Publicado: (2016)

Balancing benefits and risks in the era of biologics
por: Adami, Giovanni, et al.
Publicado: (2019)

Profile of romosozumab and its potential in the management of osteoporosis
por: Lim, Sian Yik, et al.
Publicado: (2017)

Denosumab versus romosozumab for postmenopausal osteoporosis treatment
por: Kobayakawa, Tomonori, et al.
Publicado: (2021)

Balancing risks and benefits of artificial intelligence in the health sector
por: Goodman, Kenneth, et al.
Publicado: (2020)

Neurosurgical innovation: balancing the risks and benefits of technical novelty
por: Cohen-Gadol, Aaron A.
Publicado: (2019)

Polygenic risk scores and rheumatic diseases
por: Brown, Matthew A., et al.
Publicado: (2021)

Romosozumab-aqqg in the Treatment of Osteoporosis in a Patient With Hypophosphatasia
por: Khanjee, Naveed, et al.
Publicado: (2022)

Impact of romosozumab on serum calcium concentration and factors predicting the fluctuations in calcium concentration upon romosozumab administration: A multicenter retrospective study
por: Inose, Hiroyuki, et al.
Publicado: (2022)

Successful treatment of humeral shaft nonunion with romosozumab: A case report
por: Lee, Sang Yang, et al.
Publicado: (2021)

Efficacy and Safety of Romosozumab Among Postmenopausal Women With Osteoporosis and Mild‐to‐Moderate Chronic Kidney Disease
por: Miller, Paul D, et al.
Publicado: (2022)

Skeletal responses to romosozumab after 12 months of denosumab
por: McClung, Michael R., et al.
Publicado: (2021)

T‐Score as an Indicator of Fracture Risk During Treatment With Romosozumab or Alendronate in the ARCH Trial
por: Cosman, Felicia, et al.
Publicado: (2020)

The potential role of 'non-rheumatic’ therapies in rheumatic disease
por: Massarotti, Elena M, et al.
Publicado: (2013)

Treatment with biologics during pregnancy in patients with rheumatic diseases
por: Förger, Frauke
Publicado: (2017)

Balancing gastrointestinal benefit–risk in individuals who are prescribed NSAIDs for arthritis
por: Bijlsma, Johannes W. J.
Publicado: (2010)

Balancing Benefits and Risks: Do Inhaled Corticosteroids Modify the Lung Microbiome?
por: Singh, Shivani, et al.
Publicado: (2021)

Vitiligo progression in a patient undergoing romosozumab treatment for osteoporosis
por: Trepanowski, Nicole, et al.
Publicado: (2023)

Pregnancy and Lactation-Associated Osteoporosis Successfully Treated with Romosozumab: A Case Report
por: Kaneuchi, Yoichi, et al.
Publicado: (2022)

Risk Factors Associated with Estimated Glomerular Filtration Rate in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis after Treatment with Biological Disease Modifying Anti-Rheumatic Drugs
por: Lee, Sung Won
Publicado: (2018)

Benefits of Probiotics in Rheumatic Diseases
por: Oliviero, Francesca, et al.
Publicado: (2020)

Tuberculosis in Children with Rheumatic Diseases Treated with Biologic Disease-Modifying Anti-Rheumatic Drugs
por: Kavadichanda, Chengappa, et al.
Publicado: (2021)

Romosozumab and Blosozumab: Alternative Drugs of Mechanical Strain-Related Stimulus Toward a Cure for Osteoporosis
por: Sugiyama, Toshihiro, et al.
Publicado: (2015)

Cost-effectiveness of romosozumab for the treatment of postmenopausal women at very high risk of fracture in Canada
por: Goeree, Ron, et al.
Publicado: (2022)

Balancing the Risks and Benefits of Long‐Term Antiplatelet Therapies for Cardiovascular Disease: Clinical, Research, and Regulatory Implications
por: Alfredsson, Joakim, et al.
Publicado: (2015)

Romosozumab: a novel bone anabolic treatment option for osteoporosis?
por: Kerschan-Schindl, Katharina
Publicado: (2019)

Romosozumab efficacy and safety in European patients enrolled in the FRAME trial
por: Langdahl, Bente, et al.
Publicado: (2022)

Romosozumab Enhances Vertebral Bone Structure in Women With Low Bone Density
por: Poole, Kenneth ES, et al.
Publicado: (2021)

Protons pump inhibitor treatment and lower gastrointestinal bleeding: Balancing risks and benefits
por: Lué, Alberto, et al.
Publicado: (2016)

POOR ADHERENCE TO DRUG TREATMENT IN CHILDREN AND ADOLESCENTS WITH AUTOIMMUNE RHEUMATIC DISEASES
por: Silva, Clovis Artur
Publicado: (2019)

Drug trials: Risk, benefit analysis
por: Damle, S. G.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_7cm0pt5jdtnao6l29ian3lignm